Denali Therapeutics (DNLI) Amortizatization of Intangibles (2024 - 2026)
Denali Therapeutics (DNLI) posted quarterly Amortizatization of Intangibles of $916000.0 for Q1 2026, up 3.27% year-over-year from $887000.0 in Q1 2025, and little changed quarter-over-quarter from $916000.0 in Q4 2025.
Denali Therapeutics (DNLI) Amortizatization of Intangibles (2024 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Amortizatization of Intangibles for 3 consecutive years, with $916000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 3.27% year-over-year to $916000.0; the TTM figure through Mar 2026 stood at $3.6 million (up 74.28% YoY), while the FY2025 annual figure was $3.6 million, up 203.17% from the prior year.
- Amortizatization of Intangibles held at $916000.0 in Q1 2026 per DNLI's latest filing, from $916000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $916000.0 in Q4 2025 and bottomed at $400000.0 in Q3 2024.
- Historically, Amortizatization of Intangibles has averaged $816571.4 across 3 years, with a median of $900000.0 in 2025.
- Annual changes were most pronounced in 2025 — Amortizatization of Intangibles surged 125.0% — and 2026, when it grew 3.27%.
- Denali Therapeutics' Amortizatization of Intangibles stood at $797000.0 in 2024, then increased by 14.93% to $916000.0 in 2025, then changed by 0.0% to $916000.0 in 2026.
- Business Quant data shows DNLI's Amortizatization of Intangibles at $916000.0 in Q1 2026, $916000.0 in Q4 2025, and $900000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.33 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 678,000.00 |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 915,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 915,000.00 |
| Jun 30, 2026 | 915,000.00 |
| Mar 31, 2026 | 916,000.00 |
| Mar 31, 2026 | 916,000.00 |
| Dec 31, 2025 | 916,000.00 |
| Dec 31, 2025 | 916,000.00 |
| Sep 30, 2025 | 900,000.00 |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Mar 31, 2025 | 887,000.00 |
| Mar 31, 2025 | 887,000.00 |
| Dec 31, 2024 | 797,000.00 |
| Dec 31, 2024 | 797,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Sep 30, 2024 | 400,000.00 |